1. Home /
  2. Biotechnology

Biotechnology

2 Biotech Names See Directors Direct Cash to Their Shares

2 Biotech Names See Directors Direct Cash to Their Shares

The stock purchases by the insiders are at companies developing treatments for breast cancer and schizophrenia.

Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says

Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says

That's Rule No. 5 of his '5 Rules for Trimming Your Winning Positions.'

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Shares of Pfizer rise Thursday after the drugmaker is named a 'top pick' at Credit Suisse following a meeting the analysts had with Pfizer's management team.

Colfax Strikes Deal to Sell Air and Gas Unit for $1.8 Billion

Colfax Strikes Deal to Sell Air and Gas Unit for $1.8 Billion

Colfax strikes a deal to sell its air and gas handling division to private-equity firm KPS Capital Partners for approximately $1.8 billion.

ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

Shares of ImmunoGen plunge after the U.S. Food and Drug Administration requests additional trials to 'evaluate the safety and efficacy' of one of its cancer-fighting treatments.

Vascular Biogen Expected to Lose 12 Cents a Share

Vascular Biogen Expected to Lose 12 Cents a Share

Vascular Biogen revenue expected to rise 605.5% to $1.2 million.

EDAP TMS Expected to Earn 2 Cents a Share

EDAP TMS Expected to Earn 2 Cents a Share

EDAP TMS revenue expected to rise 32.4% to $14.4 million.

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Shares of Puma Biotechnology plunge after the company reveals that more patients than expected have discontinued treatment with its breast cancer drug, Nerlynx, prompting several analyst downgrades.

Hopeful Signs for These 2 Small Biotech Stocks

Hopeful Signs for These 2 Small Biotech Stocks

Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.

Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal

Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal

Novartis gets a potentially blockbuster eye drug and Takeda gets to unload some debt and employees it took on when it purchased Shire.